Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Conmed Corp (NYSE: CNMD) was $55.19 for the day, up 2.18% from the previous closing price of $54.01. In other words, the price has increased by $2.18 from its previous closing price. On the day, 0.46 million shares were traded. CNMD stock price reached its highest trading level at $55.64 during the session, while it also had its lowest trading level at $54.045.
Ratios:
Our analysis of CNMD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 50.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.52. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.88.
On April 28, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $55.
JP Morgan Downgraded its Overweight to Neutral on February 06, 2025, whereas the target price for the stock was revised from $85 to $70.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 07 ’25 when Garner Todd W sold 598 shares for $52.45 per share. The transaction valued at 31,365 led to the insider holds 0 shares of the business.
Garner Todd W bought 598 shares of CNMD for $31,365 on Aug 07 ’25. On May 05 ’25, another insider, Farkas Charles, who serves as the Director of the company, sold 4,000 shares for $56.94 each. As a result, the insider received 227,768 and left with 16,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 1708406400 and an Enterprise Value of 2556294400. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.58, and their Forward P/E ratio for the next fiscal year is 11.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.29 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 1.927 whereas that against EBITDA is 11.616.
Stock Price History:
The Beta on a monthly basis for CNMD is 1.18, which has changed by -0.17380238 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, CNMD has reached a high of $78.19, while it has fallen to a 52-week low of $46.00. The 50-Day Moving Average of the stock is 4.80%, while the 200-Day Moving Average is calculated to be -9.73%.
Shares Statistics:
CNMD traded an average of 447.59K shares per day over the past three months and 711550 shares per day over the past ten days. A total of 30.95M shares are outstanding, with a floating share count of 30.16M. Insiders hold about 2.57% of the company’s shares, while institutions hold 111.80% stake in the company. Shares short for CNMD as of 1753920000 were 2096118 with a Short Ratio of 4.68, compared to 1751241600 on 2273055. Therefore, it implies a Short% of Shares Outstanding of 2096118 and a Short% of Float of 9.25.
Dividends & Splits
With its trailing 12-month dividend rate of 0.8, CNMD has a forward annual dividend rate of 0.80. Against a Trailing Annual Dividend Yield of 0.014812073The stock’s 5-year Average Dividend Yield is 0.88. The current Payout Ratio is 18.82% for CNMD, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2001-09-10 when the company split stock in a 3:2 ratio.
Earnings Estimates
The current market rating for Conmed Corp (CNMD) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.32, with high estimates of $1.36 and low estimates of $1.27.
Analysts are recommending an EPS of between $4.5 and $4.43 for the fiscal current year, implying an average EPS of $4.47. EPS for the following year is $4.78, with 6.0 analysts recommending between $4.99 and $4.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $337.3M to a low estimate of $332.5M. As of the current estimate, Conmed Corp’s year-ago sales were $316.7MFor the next quarter, 6 analysts are estimating revenue of $369.1M. There is a high estimate of $370.7M for the next quarter, whereas the lowest estimate is $367.69M.
A total of 6 analysts have provided revenue estimates for CNMD’s current fiscal year. The highest revenue estimate was $1.37B, while the lowest revenue estimate was $1.37B, resulting in an average revenue estimate of $1.37B. In the same quarter a year ago, actual revenue was $1.31BBased on 6 analysts’ estimates, the company’s revenue will be $1.44B in the next fiscal year. The high estimate is $1.46B and the low estimate is $1.42B.
